ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Operating Income
Profit from core operations after operating expenses, before interest and taxes.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$46.11M, compared with -$66.77M a year earlier. Trailing-twelve-month operating income was -$156.87M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -88.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$46.11M-18.8% QoQ
- Last fiscal yearDec 2025
- -$177.53M-88.2% YoY
- LTMMar 2026
- -$156.87M-11.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.9% | +100.0% | +69.1 pp |
| 1 year | -88.2% | +100.0% | +188.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (177.53M) USD
- Year-over-year change
- -88.2%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (177.53M) | -88.2% |
| FY2024 | 2024-12-31 | (94.31M) | -26.4% |
| FY2023 | 2023-12-31 | (74.59M) | -102.1% |
| FY2022 | 2022-12-31 | (36.91M) | -324.4% |
| FY2021 | 2021-12-31 | (8.7M) | — |
Operating Income vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 operating income of -$156.87M is the 8th highest of the 11 companies compared; the peer median is -$140.27M.
- Its year-over-year change of -11.7% is the 7th highest of 11, against a peer median of -4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $971.51M | +38.8% | +63.0% | 39.9% | |
| LTM Mar 2026 | $29.49M | -20.8% | +16.3% | 13.0% | |
| LTM Jun 2025 | -$19.7M | +83.7% | — | 3.3% | |
| LTM Mar 2026 | -$53.27M | -1230.0% | — | — | |
| LTM Jun 2026 | -$137.63M | +38.7% | — | 81.0% | |
| LTM Mar 2026 | -$142.91M | -25.7% | — | — | |
| LTM Mar 2026 | -$149.91M | -2.2% | — | — | |
| LTM Mar 2026 | -$156.87M | -11.7% | — | — | |
| LTM Sep 2026 | -$177.66M | -23.4% | — | — | |
| LTM Mar 2026 | -$183.47M | +49.1% | — | 81.4% | |
| LTM Jun 2026 | -$264M | -6.9% | — | 58.7% | |
| Peer median (excluding AVBP) | -$140.27M | -4.6% | +39.6% | 49.3% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.